Long term follow-up of the randomized MetaspHER study comparing intravenous versus subcutaneous trastuzumab in patients with HER2-positive metastatic breast cancer

Data from the final analysis of the MetaspHER trial—which studied preference of subcutaneous (H-SC) vs intravenous (H-IV) trastuzumab among patients with HER2-positive metastatic breast cancer—showed that safety was consistent with the known H-IV and H-SC profiles and that there was no safety concern associated with prolonged exposure to H-SC. In the trial, 113 patients were randomly assigned to receive 3 cycles of 600 mg fixed-dose H-SC, followed by 3 cycles of standard H-IV, or the reverse sequence, and after the cross-over period, all patients except two pursued H-SC.